Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13-14
pubmed:dateCreated
2006-12-12
pubmed:abstractText
Chronic cyclosporine (CsA) nephrotoxicity is a relevant factor in the pathogenesis of chronic allograft nephropathy. Pioglitazone is an agonist of PPARgamma, capable of reducing chronic inflammation. We investigated the capacity of pioglitazone in preventing renal dysfunction. Adult male Wistar rats were assigned to: Vehicle (olive oil 1 ml/kg/day), CsA (10 mg/kg/day) alone and with pioglitazone (5 or 10 mg/kg/day). The animals were sacrificed at 28 days, where blood (serum creatinine ratio, CR) and kidney samples (arteriolopathy analyses) were collected. The mRNA transcripts of TGF-beta1, PAI-1, Smad3 and 7 were evaluated by real-time PCR. As expected, CsA treatment significantly decreased renal function that peaked at day 28, compared with vehicle (CR=1.29+/-0.03 vs. 0.95+/-0.14, p<0.05). In contrast, the administration of pioglitazone 5 or 10 mg/kg combined with CsA resulted in better renal function (CR=1.09+/-0.05 and 1.14+/-0.14, respectively, p<0.05). Animals treated with CSA showed relevant arteriolopathy (49.5+/-2.86%) and pioglitazone administration significantly limited it (37.0+/-3.59% and 36.6+/-1.72%, respectively, 5 or 10 mg/kg, p<0.05). In CsA-treated animals (alone and with pioglitazone), TGF-beta1 and Smad3 increased significantly. In animals treated with CsA and pioglitazone (5 mg/kg), PAI-1 was significantly lower than CsA alone (3.96+/-0.92 vs. 7.53+/-1.38, p<0.05). Interestingly, the administration of pioglitazone 5 or 10 mg/kg was associated with an increase in Smad7 (1.79+/-0.25 and 1.75+/-0.19, respectively), compared to vehicle and to CsA-treated groups (1.08+/-0.17 and 1.17+/-0.19, respectively, p<0.05). These data provide evidence that pioglitazone acts through down regulation of pro-fibrotic cytokine PAI-1 and overexpression of the regulatory Smad7.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine, http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine, http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Madh3 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activator Inhibitor 1, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger, http://linkedlifedata.com/resource/pubmed/chemical/Smad3 Protein, http://linkedlifedata.com/resource/pubmed/chemical/Smad7 Protein, http://linkedlifedata.com/resource/pubmed/chemical/Smad7 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones, http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta1, http://linkedlifedata.com/resource/pubmed/chemical/pioglitazone
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1567-5769
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1943-51
pubmed:meshHeading
pubmed-meshheading:17161347-Animals, pubmed-meshheading:17161347-Arterioles, pubmed-meshheading:17161347-Blood Pressure, pubmed-meshheading:17161347-Body Weight, pubmed-meshheading:17161347-Creatinine, pubmed-meshheading:17161347-Cyclosporine, pubmed-meshheading:17161347-Drug Interactions, pubmed-meshheading:17161347-Gene Expression, pubmed-meshheading:17161347-Hypoglycemic Agents, pubmed-meshheading:17161347-Immunosuppressive Agents, pubmed-meshheading:17161347-Kidney, pubmed-meshheading:17161347-Kidney Diseases, pubmed-meshheading:17161347-Male, pubmed-meshheading:17161347-Plasminogen Activator Inhibitor 1, pubmed-meshheading:17161347-RNA, Messenger, pubmed-meshheading:17161347-Rats, pubmed-meshheading:17161347-Rats, Wistar, pubmed-meshheading:17161347-Smad3 Protein, pubmed-meshheading:17161347-Smad7 Protein, pubmed-meshheading:17161347-Thiazolidinediones, pubmed-meshheading:17161347-Transforming Growth Factor beta1
pubmed:year
2006
pubmed:articleTitle
Pioglitazone limits cyclosporine nephrotoxicity in rats.
pubmed:affiliation
Laboratório de Imunologia Clínica e Experimental, Division of Nephrology, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't